BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 125 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $48,480,000 | -21.2% | 5,955,762 | -21.9% | 4.80% | -38.3% |
| Q4 2018 | $61,512,000 | +1.0% | 7,622,256 | -4.5% | 7.78% | -18.0% |
| Q3 2018 | $60,874,000 | +42.1% | 7,978,275 | +6.7% | 9.49% | +59.7% |
| Q2 2018 | $42,851,000 | -99.9% | 7,478,275 | 0.0% | 5.94% | +12.1% |
| Q1 2018 | $35,671,000,000 | +152784.5% | 7,478,275 | +57.4% | 5.30% | +33.1% |
| Q4 2017 | $23,332,000 | +171.9% | 4,751,883 | +190.2% | 3.98% | +138.5% |
| Q3 2017 | $8,580,000 | +10.7% | 1,637,332 | +33.7% | 1.67% | +4.8% |
| Q4 2016 | $7,754,000 | +142.5% | 1,225,000 | +69.0% | 1.59% | +95.5% |
| Q3 2016 | $3,197,000 | – | 725,000 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |